IceCure Medical Ltd. (NASDAQ:ICCM) Receives Consensus Recommendation of “Hold” from Analysts

IceCure Medical Ltd. (NASDAQ:ICCM) has been given an average recommendation of “Hold” by the five brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $62.70.

ICCM has been the subject of several recent research reports. Maxim Group decreased their price target on IceCure Medical from $90.00 to $30.00 and set a “buy” rating for the company in a report on Thursday, May 14th. Alliance Global Partners started coverage on shares of IceCure Medical in a research note on Monday, May 4th. They issued a “buy” rating on the stock. Wall Street Zen raised shares of IceCure Medical to a “sell” rating in a research note on Sunday, July 12th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of IceCure Medical in a research report on Friday, July 17th.

Institutional Investors Weigh In On IceCure Medical

Institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC acquired a new position in shares of IceCure Medical during the 4th quarter worth $67,000. Concurrent Investment Advisors LLC purchased a new stake in IceCure Medical during the fourth quarter worth about $48,000. Finally, Virtu Financial LLC purchased a new stake in IceCure Medical during the fourth quarter worth about $39,000. Hedge funds and other institutional investors own 0.62% of the company’s stock.

IceCure Medical Stock Performance

Shares of IceCure Medical stock opened at $3.33 on Friday. The company has a market capitalization of $11.42 million, a P/E ratio of -0.46 and a beta of 0.43. IceCure Medical has a 1 year low of $2.12 and a 1 year high of $42.00. The company’s fifty day moving average is $5.03 and its two-hundred day moving average is $11.75.

IceCure Medical (NASDAQ:ICCM) last announced its earnings results on Tuesday, May 12th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.03). The business had revenue of $0.91 million during the quarter, compared to analysts’ expectations of $1.34 million. IceCure Medical had a negative net margin of 441.60% and a negative return on equity of 211.73%. As a group, equities analysts expect that IceCure Medical will post -3.51 earnings per share for the current year.

About IceCure Medical

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.